Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain

Fig. 4

Functionality of Jchain TCRs in CD8 and CD4 T cells. A–C Jchain A1, A24, A3 and A11 restricted TCRs were sequenced and introduced with murine constant beta domains (mTCR) into CD4 and CD8 T cells. After mTCR enrichment functionality was assessed. A TCR T cells were stained with the respective Jchain pHLA tetramers and analyzed by FACS. TCR T cells were gated on mTCR +. Parental T-cell clones were included as positive controls and CMV TCR T cells were included as negative controls. B Endogenous recognition of JCHAIN and HLA (A1, A24, A3, or A11) transduced K562 cells by Jchain TCR CD4 and CD8 T cells. HLA only transduced K562 cells were included as negative control. Values and means of technical duplicates are shown. C TCR-transduced CD8 T cells were used for 6-h chromium release assays to study target cell lysis in E/T ratios 10:1 and 1:1. T cells were co-cultured with U266 MM cells, UM9 MM cells or antigen negative K562 cells transduced with (+ HLA) or naturally expressing (HLApos) target HLA molecules. CMV TCR T cells were used as a negative control. Values and means of technical triplicates are shown

Back to article page